Patent ID: 8574575
Filing Date: 2013-11-05
Classification: A61K,A61P,C07K

Abstract:
1. A method of treating cancer comprising: a. obtaining a humanized anti-TROP2 antibody or antigen-binding fragment thereof comprising human light and heavy chain framework region (FR) and constant region sequences and the light chain variable region complementarity determining region (CDR) sequences CDR1KASQDVSIAVA (SEQ ID NO:28), CDR2SASYRYT (SEQ ID NO:29) and CDR3QQHYITPLT (SEQ ID NO:30) and the heavy chain variable region CDR1NYGMN (SEQ ID NO:31), CDR2 WINTYTGEPTYTDDFKG (SEQ ID NO:32) and CDR3GGFGSSYWYFDV (SEQ ID NO:33); and b. administering the antibody to a subject with a TROP-2 positive cancer; wherein the antibody is a naked antibody or is conjugated to at least one therapeutic agent selected from the group consisting of a drug, an immunomodulator, a hormone, an enzyme, a growth factor, a radionuclide, an antisense oligonucleotide, an anti-angiogenic agent and a pro-apoptotic agent and wherein the humanized anti-TROP-2 antibody or fragment thereof has a heavy chain allotype G1m3, a heavy chain isoallotype nG1 m1,2 and a light chain allotype Km3.